Abstract
diabetic nephropathy (DN) remains the single most common cause of end-stage kidney disease, necessitating dialysis or transplantation, in the Western world. Hence, novel therapies beyond tight blood pressure and glycemic control are required to slow or reverse progression of nephropathy in patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have